effects of rexulti on qtc and prolactin
Rexulti theoretically has a lower risk of extrapyramidal symptoms and prolactin elevation, because of its enhanced serotonin antagonism Rexulti has a high affinity for serotonin 5HT1A receptors, where it is a partial agonist, and 5HT2A receptors, where it is an antagonist. Abilify affects the same receptors, but to a lesser extent. This may give Rexulti an advantage over Abilify.
At a dose 3-times the MRHD for the treatment of schizophrenia and 4-times the MRHD for adjunctive therapy to antidepressants for the treatment of MDD, REXULTI does not prolong the QTc interval to any clinically relevant extent.